AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36762424 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥75 ng/L without ischemic features
Number of subjects: 4553
Study 36762782 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus for 6 months
Number of subjects: 18
Study 36762851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ide-cel
Number of subjects: 386
Study 36762851 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 386
Study 36762852 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 456
Study 36762852 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 456
Study 36762865 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus medical care
Number of subjects: 352
Study 36762865 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 352
Study 36762880 — intervention group
Group type: EXPERIMENTAL
Intervention: eDiagnoses (new medical computerized tool)
Number of subjects: 446
Study 36762880 — intervention group
Group type: COMPARATOR
Intervention: medDiagnoses (standard clinical approach)
Number of subjects: 446
Study 36762893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and disability drivers management model
Number of subjects: 0
Study 36762930 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120-reactive monoclonal antibodies (mAbs) isolated from participants
Number of subjects: 0
Study 36762930 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced gp120-specific antibody lineages
Number of subjects: 0
Study 36763114 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided bilateral thoracic paravertebral blocks (TPVBs) in Group NO (BMI < 30)
Number of subjects: 82
Study 36763114 — intervention group
Group type: COMPARATOR
Intervention: US-guided bilateral thoracic paravertebral blocks (TPVBs) in Group O (BMI ≥ 30)
Number of subjects: 82
Study 36763159 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 144
Study 36763159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 36763183 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week web-based dietary intervention with daily text messages
Number of subjects: 50
Study 36763183 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 36763243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 569
Study 36763307 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID) of natalizumab (≤ 9 infusions/year)
Number of subjects: 303
Study 36763307 — intervention group
Group type: COMPARATOR
Intervention: Standard interval dosing (SID) of natalizumab (≥ 11 infusions/year)
Number of subjects: 303
Study 36763307 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID)
Number of subjects: 303
Study 36763307 — intervention group
Group type: COMPARATOR
Intervention: Standard interval dosing (SID)
Number of subjects: 303
Study 36763328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 445
Study 36763328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 445
Study 36763328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 36763327 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoziborole (20-1200 mg single oral dose)
Number of subjects: 128
Study 36763327 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (in additional cohorts)
Number of subjects: 128
Study 36763327 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules versus tablets (in additional cohorts)
Number of subjects: 128
Study 36763327 — intervention group
Group type: EXPERIMENTAL
Intervention: 960-mg tablet cohort (in additional cohorts)
Number of subjects: 128
Study 36763359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy (CLT)
Number of subjects: 72
Study 36763359 — intervention group
Group type: COMPARATOR
Intervention: Sham laser therapy (SLT)
Number of subjects: 72
Study 36763358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 2046
Study 36763358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 2046
Study 36763358 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg subcutaneous twice daily)
Number of subjects: 2046
Study 36763521 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced nonopioid general anesthesia with lidocaine
Number of subjects: 772
Study 36763521 — intervention group
Group type: COMPARATOR
Intervention: Balanced opioid general anesthesia with sufentanil
Number of subjects: 772
Study 36763537 — intervention group
Group type: EXPERIMENTAL
Intervention: KPd (carfilzomib 20/27 mg/m2, pomalidomide 4 mg, dexamethasone 40 mg)
Number of subjects: 94
Study 36763537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dara-KPd (KPd with daratumumab)
Number of subjects: 94
Study 36763614 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea Tree Oil
Number of subjects: 0
Study 36763614 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Number of subjects: 0
Study 36763614 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36763627 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device with UVR-sensing technology and mobile application notifications about exposure and prompts to use sunscreen.
Number of subjects: 386
Study 36763627 — intervention group
Group type: COMPARATOR
Intervention: Control group received the device and a separate research mobile application without exposure information or notifications.
Number of subjects: 386
Study 36763857 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 36763857 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 36763857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36763857 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events (AEs)
Number of subjects: 0
Study 36763857 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease
Number of subjects: 0
Study 36763857 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 0
Study 36763878 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1303
Study 36763878 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 2 mg
Number of subjects: 1303
Study 36763878 — intervention group
Group type: EXPERIMENTAL
Intervention: All-baricitinib (any dose)
Number of subjects: 1303
Study 36763879 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg (continuous dosing)
Number of subjects: 526
Study 36763879 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg (downtitration)
Number of subjects: 526
Study 36763879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (treatment withdrawal, 4-mg cohort)
Number of subjects: 526
Study 36763879 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg (continuous dosing)
Number of subjects: 526
Study 36763879 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg (downtitration)
Number of subjects: 526
Study 36763879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (treatment withdrawal, 2-mg cohort)
Number of subjects: 526
Study 36763879 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg (downtitration)
Number of subjects: 526
Study 36763879 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 4 mg (treatment withdrawal)
Number of subjects: 526
Study 36763879 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib 2 mg (treatment withdrawal)
Number of subjects: 526
Study 36763899 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (ONA) injections (1.5 U/injection site)
Number of subjects: 20
Study 36763899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 20
Study 36763919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal treatment with gel containing 600 IU/mL of oxytocin
Number of subjects: 50
Study 36763919 — intervention group
Group type: COMPARATOR
Intervention: Control group (gel alone)
Number of subjects: 50
Study 36763929 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 92
Study 36763936 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib + Cetuximab
Number of subjects: 95
Study 36763945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide (B-DRC)
Number of subjects: 204
Study 36763945 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone-Rituximab-Cyclophosphamide (DRC)
Number of subjects: 204
Study 36764101 — intervention group
Group type: EXPERIMENTAL
Intervention: Step training with rhythmic cuing
Number of subjects: 48
Study 36764316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 345
Study 36764316 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 345
Study 36764323 — intervention group
Group type: EXPERIMENTAL
Intervention: CYAD-01 (autologous NKG2D-based CAR T-cell therapy)
Number of subjects: 16
Study 36764326 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg acute treatment (n=19)
Number of subjects: 35
Study 36764326 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily for 3 weeks (n=16)
Number of subjects: 35
Study 36764326 — intervention group
Group type: COMPARATOR
Intervention: Placebo acute treatment (n=12)
Number of subjects: 35
Study 36764326 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks (n=15)
Number of subjects: 35
Study 36764513 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) defined as an apnea hypopnea index ≥ 15 events/h
Number of subjects: 1920
Study 36764513 — intervention group
Group type: COMPARATOR
Intervention: No OSA (control group)
Number of subjects: 1920
Study 36764628 — intervention group
Group type: EXPERIMENTAL
Intervention: OJ with 22g of oat bran containing 6g of β-glucan
Number of subjects: 0
Study 36764628 — intervention group
Group type: COMPARATOR
Intervention: OJ without oat bran
Number of subjects: 0
Study 36764680 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-directed care
Number of subjects: 59
Study 36764712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 Gy/6 fractions of LDRT
Number of subjects: 114
Study 36764712 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Gy/6 fractions of LDRT
Number of subjects: 114
Study 36764712 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 114
Study 36764715 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modality medical imaging (brain MRI, retinal fundus photograph, fundus OCT, ultrasonography of ICA) every 2-4 years
Number of subjects: 1000
Study 36764718 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 100
Study 36764718 — intervention group
Group type: COMPARATOR
Intervention: Placebo SMT
Number of subjects: 100
Study 36764835 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related text warning
Number of subjects: 961
Study 36764835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar pictorial warning
Number of subjects: 961
Study 36764835 — intervention group
Group type: EXPERIMENTAL
Intervention: Health pictorial warning
Number of subjects: 961
Study 36764835 — intervention group
Group type: COMPARATOR
Intervention: No-warning control
Number of subjects: 961
Study 36764892 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal stress CMR
Number of subjects: 2349
Study 36764892 — intervention group
Group type: COMPARATOR
Intervention: Normal stress CMR
Number of subjects: 2349
Study 36764892 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography
Number of subjects: 2349
Study 36764892 — intervention group
Group type: COMPARATOR
Intervention: Downstream costs
Number of subjects: 2349
Study 36764917 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE-guided LAAC with the Watchman FLX device
Number of subjects: 100
Study 36764966 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 0
Study 36764966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36765309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention components to support PWIDLH to reduce drug use and improve mental health and engagement in HIV care.
Number of subjects: 0
Study 36765312 — intervention group
Group type: EXPERIMENTAL
Intervention: KopOpOuders-PTSD (treatment as usual + intervention)
Number of subjects: 142
Study 36765312 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control condition)
Number of subjects: 142
Study 36765313 — intervention group
Group type: EXPERIMENTAL
Intervention: MINS (myocardial injury after non-cardiac surgery)
Number of subjects: 64
Study 36765313 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without MINS)
Number of subjects: 64
Study 36765318 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)-based regimens
Number of subjects: 761
Study 36765318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arsenic trioxide (oral-ATO)-based regimens
Number of subjects: 761
Study 36765318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 761
Study 36765332 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of 4 mg Triamcinolone Acetonide (TA)
Number of subjects: 16
Study 36765344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mzake peer group intervention delivered by trained community volunteers
Number of subjects: 0
Study 36765344 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants served as controls until they completed the program)
Number of subjects: 0
Study 36765344 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth subsample
Number of subjects: 0
Study 36765344 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult subsample
Number of subjects: 0
Study 36765352 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior muscle-preserving selective laminectomy
Number of subjects: 300
Study 36765352 — intervention group
Group type: COMPARATOR
Intervention: Posterior laminectomy with fusion
Number of subjects: 300
Study 36765414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 12924
Study 36765414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support with patient education materials (CDS-E)
Number of subjects: 12924
Study 36765414 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 12924
Study 36765421 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA only
Number of subjects: 105
Study 36765421 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen and t-PA
Number of subjects: 105
Study 36765421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase infusion (24 h)
Number of subjects: 105
Study 36765432 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual genetics navigator
Number of subjects: 759
Study 36765432 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing by genetic health coaches
Number of subjects: 759
Study 36765432 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 759
Study 36765556 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium electroporation treatment
Number of subjects: 9
Study 36765709 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy (RT)
Number of subjects: 3875
Study 36765709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor bed boost
Number of subjects: 3875
Study 36765709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node RT
Number of subjects: 3875
Study 36765709 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 3875
Study 36765709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node surgery
Number of subjects: 3875
Study 36765803 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for primary tumors of the spine
Number of subjects: 68
Study 36765803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 68
Study 36765803 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 68
Study 36765803 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection considered 'Enneking appropriate' (EA)
Number of subjects: 68
Study 36765803 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival analysis
Number of subjects: 68
Study 36765803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year follow-up
Number of subjects: 68
Study 36765881 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive LAB immunohistochemistry (IHC) expression (>5% of tumor cells)
Number of subjects: 256
Study 36765948 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic salvage radiotherapy (SSRT)
Number of subjects: 25
Study 36767448 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (before 09:00 a.m.)
Number of subjects: 0
Study 36767448 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (after 7:00 p.m.)
Number of subjects: 0
Study 36769445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (0.5 Gy)
Number of subjects: 46
Study 36769543 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (8 weeks)
Number of subjects: 25
Study 36769543 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (first 4 weeks)
Number of subjects: 25
Study 36769752 — intervention group
Group type: COMPARATOR
Intervention: Pilates method plus placebo PBMT/sMF
Number of subjects: 33
Study 36769752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method plus active PBMT/sMF
Number of subjects: 33
Study 36769752 — intervention group
Group type: EXPERIMENTAL
Intervention: Only active PBMT/sMF
Number of subjects: 33
Study 36769813 — intervention group
Group type: EXPERIMENTAL
Intervention: CatBoostClassifier
Number of subjects: 6495
Study 36769813 — intervention group
Group type: COMPARATOR
Intervention: Traditional logistic regression and eleven ML algorithms
Number of subjects: 6495
Study 36769813 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP level
Number of subjects: 6495
Study 36769813 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified by SHAP
Number of subjects: 6495
Study 36769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired COVID-19 infections
Number of subjects: 1369
Study 36769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient care staff (especially nursing assistants)
Number of subjects: 1369
Study 36769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff from radiology/functional assessment units and stretcher services
Number of subjects: 1369
Study 36769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff working on wards with COVID-19 clusters
Number of subjects: 1369
Study 36769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric wards
Number of subjects: 1369
Study 36769854 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational risk factors
Number of subjects: 1369
Study 36771199 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplement
Number of subjects: 168
Study 36771199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 36771273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk supplemented with preterm donor milk (PDM)
Number of subjects: 120
Study 36771273 — intervention group
Group type: COMPARATOR
Intervention: Mother's own milk supplemented with term donor milk (TDM)
Number of subjects: 120
Study 36772802 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the Premotor Cortex
Number of subjects: 0
Study 36772948 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication treatment
Number of subjects: 25
Study 36772948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 36772948 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-free condition
Number of subjects: 25
Study 36772985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma plasma-derived exosomes (100 μg and 200 μg)
Number of subjects: 30
Study 36772985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma plasma-derived exosomes (50 μg)
Number of subjects: 30
Study 36772985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exosomal protein (100 μg) with bone marrow stromal cells
Number of subjects: 30
Study 36772985 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from trauma patients
Number of subjects: 30
Study 36773001 — intervention group
Group type: COMPARATOR
Intervention: Pilomotor function in PD patients
Number of subjects: 38
Study 36773001 — intervention group
Group type: COMPARATOR
Intervention: Sympathetic skin response (SSR) in PD patients
Number of subjects: 38
Study 36773001 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic neurocardiac function via heart rate variability in PD patients
Number of subjects: 38
Study 36773038 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang screening questionnaire
Number of subjects: 206
Study 36773038 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-specific refinement resulting in the BOSS-GAP score
Number of subjects: 206
Study 36773038 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 206
Study 36773112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam 3 g every 8 h for 8-14 days
Number of subjects: 726
Study 36773112 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1 g every 8 h for 8-14 days
Number of subjects: 726
Study 36773128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.017 × 0.025-inch stainless-steel archwire (SSAW)
Number of subjects: 30
Study 36773128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.019 × 0.025-inch stainless-steel archwire (SSAW)
Number of subjects: 30
Study 36773128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.021 × 0.025-inch β-titanium archwire (TMAW)
Number of subjects: 30